Retinoic acid plus chemotherapy for intermediate-to-high risk rhabdomyosarcoma
Part of Cancer clinical trials.
This trial tests a new combination treatment for intermediate-to-high risk rhabdomyosarcoma, a type of muscle cancer. It combines a standard chemotherapy regimen (VAC) with a vitamin A derivative called all-trans retinoic acid, which may help the chemo work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 60 years old.
- You must have been diagnosed with intermediate or high risk rhabdomyosarcoma, a cancer of the muscles (but not the pleomorphic type).
- You must be able to take care of yourself and be up and about (ECOG score 0-1).
- You must not have had any anti-cancer drug treatment in the past.
- Your blood counts, liver, kidney, and heart function must be within certain limits (checked by blood tests).
- If you are a woman who can have children, you must have a negative pregnancy test and use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans for children with rhabdomyosarcoma based on their individual risk factors. It aims to find the best therapy for each child, potentially improving outcomes.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.